Large Analysis Links Low Testosterone to Higher Cancer Mortality Risk in Men
By
David Nield
Summary
A large international analysis of 11 long-running studies involving over 26,000 men found that very low testosterone levels are associated with a significantly higher risk of dying from cancer. The research suggests low testosterone may serve as a warning signal for cancer mortality risk, though one type of cancer was noted as an exception.
Source
Twitter / XLarge Analysis Links Low Testosterone to Higher Cancer Mortality Risk in Mensciencealert.comKey quotes
· 3 pulledNow, a large new analysis suggests something else may carry a warning signal.
An international team examined 11 long-running studies involving more than 26,000 men of varying ages, with follow-up periods of at least five years.
The data showed that very low testosterone levels were associated with a significantly higher risk of dying from cancer, although one type of cancer was an exception.
You might also wanna read
Study Finds Testosterone Administration Influences Political Preferences in Weakly Affiliated Democrats
A scientific study examined the effects of testosterone administration on political preferences in 136 healthy males. The research found tha
pmc.ncbi.nlm.nih.gov·8mo agoDHEA-S hormone linked to shorter lifespan in men, but not women
Insecure men make for big business: The testosterone craze that is exploiting the masculinity crisis
Study Finds Link Between Farming Exposure and ALS Mortality Risk in Postmenopausal Women
This study, nested within the Women's Health Initiative, examined the association between farming/insecticide exposure and ALS mortality ris
karger.com·26d agoSitting For More Than 30 Minutes At a Time Linked To Higher Risk of Cancer Death
Meta-analysis: Fiber Reduces Overall Mortality by 23%, Cardiovascular Death by 26%, and Cancer Risk by 22%
A meta-analysis of 64 studies with over 3.5 million subjects found that fiber intake reduces overall mortality by 23%, cardiovascular mortal
empirical.health·8mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.